Navigation Links
STALLERGENES and Protein' eXpert Enter Into a Partnership for Producing Mites Recombinant Allergens

ANTONY, GRENOBLE France, December 13 /PRNewswire-FirstCall/ -- STALLERGENES S.A and Protein'eXpert S.A. announce they have signed a partnership agreement for developing and pharmaceutically producing mites recombinant allergens(1).

The partnership is part of the STALLERGENES "Enhanced Allergens" innovation programme for a recombinant protein treatment for sublingual desensitisation of allergy to mites. This second-generation treatment is made up of the recombinant allergens Der p 1 and Der p 2 in the form of a fusion protein, combined with an adjuvant and/or a mucoadhesive formulation for facilitating recognition of the allergen by the immune system.

Protein'eXpert will handle:

- developing processes aimed at optimising the existing production protocol;

- developing and scaling up fermentation, renaturation, and purification processes;

- producing preclinical and clinical batches.

"This partnership enables us to accelerate the development of our "Enhanced Allergens" programme, and to envisage moving rapidly on to humans in a phase I study," emphasizes Philippe Moingeon, Scientific Director of STALLERGENES. Protein'eXpert has indeed recognised know-how in the field of process development and cGMP(2) biomanufacturing."

"Protein'eXpert is very pleased to be taking part in an innovative development programme in the specific field of respiratory allergy immunotherapy," declares Nicolas Mouz, Chief Scientific Director at Protein'eXpert. "'This partnership offers us an opportunity to propose our expertise in protein engineering and therapeutic protein development, and to widen our knowledge of allergens."

About the "Enhanced Allergens" programme

The combination of molecular biology tools and of formulation/adjuvanting strategies makes it possible to target better the immune system of the sublingual mucous membrane, and to improve the efficacy of desensitisation treatments. It is on this major concept that the "Enhanced Allergens" programme is based.

The active ingredient being considered is a combination of the major allergens of Dermatophagoides pteronyssinus, Der p 1 and Der p 2, expressed as a single recombinant molecule. The use of recombinant allergens makes it possible to develop products that are fully characterised, quantifiable, and reproducible.

In January 2007, a first range of product candidates was selected and underwent pharmaceutical and preclinical development. Going on to humans is scheduled for 2009, and several product candidates will be tested in parallel so as to identify, in 2010, the final prototype. A clinical development phase is scheduled for 2011.


STALLERGENES is a biopharmaceutical company specialised in desensitisation treatments for allergy-related respiratory diseases such as allergic rhino-conjunctivitis, allergic rhinitis, and allergic asthma.

A pioneer and leader in sublingual desensitisation treatments, STALLERGENES devotes 18% of its turnover to Research and Development, and in particular development of a new therapeutic class, namely sublingual desensitisation treatment in tablet form.

In 2006, STALLERGENES recorded a turnover of 126.5 million euros, half of which on markets outside France.

STALLERGENES shares are listed on Eurolist, Compartment B of the Euronext Paris Stock Exchange
Codes: ISIN FR0000065674, Reuters GEN.PA, Bloomberg GEN.FP

Additional information on STALLERGENES is available at:

About Protein'eXpert Funded in 2000 in Grenoble, France, Protein'eXpert is an expanding Contract Research & Manufacturing Organisation devoted to recombinant protein engineering & production for biomedical research applications.

Protein'eXpert also provides services for process development & scale-up optimisation, pre-clinical and clinical cGMP production via its integrated subsidiary PX'Pharma.

The combination of Protein'eXpert and PX'Pharma know-how and manufacturing capacities allows ensuring a seamless transfer from early research to clinical production stages for therapeutic protein and recombinant vaccine projects. Recently, Protein'eXpert has created a new subsidiary named PX'Monoclonals, which offers contract services for the development of murine and humanized monoclonal antibodies.

Leading player in France and Europe, Protein'eXpert intends to expand internationally and especially in North America. The 48-staff company expects a turnover of over EUR3.3 million in 2007 (of which 50% at export).

Protein'eXpert complies with ISO 9000:2000 international quality standards. The PX'Pharma facility and equipment have been inspected by AFSSAPS (France) and comply with the French and European (EMEA) GMP guidelines.

Additional information on Protein'eXpert is available at:

(1) Recombinant allergen: allergen produced by genetic engineering, unlike a natural allergen.

(2) cGMP: current Good Manufacturing Practices.

SOURCE Stallergenes
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. STALLERGENES : Strong Business Growth: +17% and Earnings Per Share up 30%
2. Stallergenes : 3rd Quarter Sales Up 17%: 9- Month Cumulative Sales Up 17%
3. STALLERGENES: ORALAIR Grasses: Positive Results of VO52.06 Paediatric Study
4. Vermillion and Collaborators Discover Protein Biomarker Associated with Peripheral Artery Disease
5. China-Biotics, Inc. Launches Shining Probiotics Protein Powder
6. When proteins, antibodies and other biological molecules kiss, a new kind of biosensor can tell
7. When proteins, antibodies and other biological molecules kiss, a new kind of biosensor can tell
8. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
9. Baxter Adds Recombinant Protein to Specialty Therapeutics Portfolio
10. Decision Biomarkers Awarded U.S. Patent for Protein Array Surface Chemistry
11. Global Experts Explore Entire Spectrum of Aids Vaccine Development
Post Your Comments:
(Date:10/8/2015)... Maryland , October 8, 2015 ... .   --> Goldman Small ... in the small cap and microcap sectors, announced ... research report on PharmaCyte Biotech, Inc. (OTCQB - ... focused on developing and preparing treatments for cancer ...
(Date:10/8/2015)... , Oct. 8, 2015 /PRNewswire/ - RepliCel Life Sciences Inc. ... company focused on the development of autologous cell therapies, today ... partnering meetings taking place in the month of October: ... Partnering Forum RepliCel will be presenting at the ... on the Mesa to be held October 7-9 in ...
(Date:10/8/2015)... Claremont, CA (PRWEB) , ... October 08, 2015 ... ... by mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene and results ... abnormally viscous and sticky mucus accumulates in the lungs. This mucus is very ...
(Date:10/7/2015)... , Oct. 7, 2015  ChromaDex Corp. ... and nutritional ingredients that creates science-based solutions for ... nutrition, and pharmaceutical products, today announced that the ... CEO and Founder, is now available for on-demand ... -->   --> ...
Breaking Biology Technology:
... form of skin cancer, afflicts more than 50,000 people in ... rise. In a study published online in Genome ... ever before into the RNA world of the melanoma tumor ... the disease. The latest high-throughput DNA sequencing ...
... ... ... ... ...
... ... report on Fermenters market. The US market for fermenters is projected to reach $180 million ... biological drugs worldwide, and growing use of disposable or single-use fermenters. , ... San Jose, California (PRWEB) February 22, 2010 -- ...
Cached Biology Technology:
(Date:10/7/2015)... Sweden , October 8, 2015 ... the revenues for Fingerprint Cards (FPC) during third quarter 2015 ... revenue guidance of around 860 MSEK that was communicated 20 ... Considering a further strengthened delivery capacity and a continued growing ... quarter 2015 is estimated to be higher than during the ...
(Date:10/2/2015)... 02 2015 ... "Enforcing the Law Using Biometrics" report to ... announced the addition of the "Enforcing the ... --> Research and Markets ( ... "Enforcing the Law Using Biometrics" report to ...
(Date:9/29/2015)... -- News facts: , ... , Minimized design shrinks PC footprint , ... embedded Fujitsu PalmSecure authentication enable enterprises to realize benefits ... that good things come in small packages, with the ... desktop and mobile portfolio. Featuring workplace design that favors ...
Breaking Biology News(10 mins):
... that the clouded leopard found on the islands of Borneo ... secretive rainforest animal was originally thought to be the same ... , Genetic analysis conducted at the U.S. National Cancer ... species is comparable to the differences between other large cat ...
... Professor of Medicine and Pharmacology at the University of ... about 265 twin pairs over the past few years, ... "By studying many traits and genes, we have started ... Studying genetic variations in twins provides scientists with data ...
... in stem cell research may mean big things for cancer ... research team at the University of Kentucky published their findings ... The researchers genetically mapped a stem cell gene and its ... investigation all the way through to the identification of the ...
Cached Biology News:
... CLS number is a new ... match Cornings product number. If ... order under the old Sigma-Aldrich ... service for assistance. ID clarifier: ...
... The GenElute Gel Extraction Kit combines silica- binding ... vacuum column format. DNA fragments of interest are ... solubilizing the gel. The Gel Solubilization Solution can ... in either TBE or TAE buffer. Extracted DNA ...
... are designed for the rapid purification of linear ... gels. The DNA band is excised from an,agarose ... within the base of the column are a ... and impurities back while allowing DNA to selectively ...
... Ultra Agarose Spin Kit is an advanced system for ... purified DNA can be used directly for any downstream ... DNA is ready to use in 56 minutes ... used for TAE and TBE gels No specialised ...
Biology Products: